Press Release: Santhera's Board of Directors Submits Amended Proposal to its Extraordinary General Meeting on December 11, 2018

Santhera Pharmaceuticals Holding AG / Santhera's Board of Directors

Submits Amended Proposal to its Extraordinary General Meeting on

December 11, 2018. Processed and transmitted by West Corporation. The

issuer is solely responsible for the content of this announcement.

Pratteln, Switzerland, December 10, 2018 - Santhera Pharmaceuticals

(SIX: SANN) announces that its Board of Directors will submit an amended

proposal to its upcoming Extraordinary General Meeting on December 11,

2018. As per the amendment and in line with the financing objective, the

Board of Directors proposes to increase the share capital by up to CHF

5,000,000.

As announced in the Invitation to the Extraordinary General Meeting

(EGM) of Shareholders (dated November 20, 2018), Santhera intends to

raise approximately CHF 50 million. To satisfy this capital need, the

Board of Directors (BoD) originally proposed to increase the Company's

ordinary share capital by a maximum of 3,500,000 registered shares with

a nominal value of CHF 1 per share, which based on the prevailing share

price at the time of announcement would have been sufficient to raise

the targeted amount.

In abidance of the Company's financing goal, the BoD is adjusting the

proposed capital increase. Under the amended proposal, the BoD plans to

increase the Company's ordinary share capital from CHF 7,527,479 by a

new maximum of CHF 5,000,000 to a new maximum of CHF 12,527,479 through

the issuance of up to 5,000,000 registered shares with a nominal value

of CHF 1 per share.

EGM agenda

Agenda and amended proposal are available on the Company's website at

www.santhera.com/investors-and-media/investor-toolbox/shareholder-meetings.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical

company focused on the development and commercialization of innovative

medicines for rare and other diseases with high unmet medical needs. The

portfolio comprises clinical stage and marketed treatments for

neuro-ophthalmologic, neuromuscular and pulmonary diseases. Santhera's

Raxone(R) (idebenone) is authorized in the European Union, Norway,

Iceland, Liechtenstein and Israel for the treatment of Leber's

hereditary optic neuropathy (LHON) and is currently commercialized in

more than 20 countries. For further information, please visit

www.santhera.com.

Raxone(R) is a trademark of Santhera Pharmaceuticals.

For further information please contact:

public-relations@santhera.com or

Eva Kalias, Head External Communications

Phone: +41 78 671 98 86

eva.kalias@santhera.com

For Investors:

investor-relations@santhera.com or

Christoph Rentsch, Chief Financial Officer

Hans Vitzthum, LifeSci Advisors

Europe: +41 61 906 89 65 US: +1 212 915 2568

christoph.rentsch@santhera.com

hans@lifesciadvisors.com

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to

subscribe for or purchase any securities of Santhera Pharmaceuticals

Holding AG. This publication may contain certain forward-looking

statements concerning the Company and its business. Such statements

involve certain risks, uncertainties and other factors which could cause

the actual results, financial condition, performance or achievements of

the Company to be materially different from those expressed or implied

by such statements. Readers should therefore not place undue reliance on

these statements, particularly not in connection with any contract or

investment decision. The Company disclaims any obligation to update

these forward-looking statements.

# # #

News Release EGM Amendment:

http://hugin.info/137261/R/2228536/875209.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Santhera Pharmaceuticals Holding AG via Globenewswire

--- End of Message ---

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24 Pratteln Switzerland

ISIN: CH0027148649;

http://www.santhera.com

(END) Dow Jones Newswires

December 10, 2018 13:00 ET (18:00 GMT)